DRP Journal

Discover Research Profit

Finance 

Hemostemix Inc (HEM.V) (OTCQB:HMTXF) In Focus After Latest Development

Jon Williams ,

Imagine you find Your Fountain of Youth™,  a treatment for your heart disease, or your peripheral arterial disease. Where might you ask? Imagine Your Fountain of Youth™ is contained within your blood. That is what Hemostemix has created. That is why they trade marked Your Fountain of Youth ™.

Hemostemix Inc. (HEM.V) (OTCQB:HMTXF), established in 2003, bestowed the World Economic Forum Technology Pioneer Award for its creation of a platform technology is the owner of 87 patents.

The patents are related to its stem cell technology, and its ability to scale production up to $12 Million per month, per manufacturing device (1+n = $12M + n). The company creates three products from the patient’s blood: angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01).  

The company is currently involved in the commercialization of ACP-01, its lead product, which has been used safely and effectively 498 times to treat critical limb ischemia (“CLI”), ischemic heart disease, and peripheral arterial disease.

Take CLI, for example, a loss of circulation (atherosclerosis) in the limbs that leads to severe chronic pain at rest, ulcerating wounds that will not heal, gangrene, and amputation. Contrasting the five-year survival rate of a CLI amputee at < 35% with the company’s phase II randomized clinical trial,  93.5% of treated limbs were saved from amputation.  

In Hemostemix’  most recent study of ischemic heart failure patients,  the Company demonstrated statistically significant results: the percent increase of left ventricle ejection fraction (the volume of blood the heart pumps) at an average of 12 months after treatment improved by 27.75%, p=0.003.

Recently, the company announced it engaged Chris McNorgan, PhD, to drive a license agreement of NCP 01 with Neuralink or its competitors, as NCP-01 promises to improve healing and signaling at the site of brain implants.  McNorgan,  the recent director at the University of Buffalo’s Computational Cognitive Neuroscience (CCN) program, completed behavioral studies of deep learning, mapping how our brains process reading, for example.    

“Your Fountain of Youth ™ sums up Hemostemix’s technology and business plan. For a phase II-III biotech company at this valuation, perhaps Hemostemix is worthy of your risk investment?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

Jon Williams

Jon graduated from the University of Michigan with a degree in finance. He is an avid investor and enjoys reporting on the markets. When he is not in front of a computer he enjoys playing golf and watching basketball.